The U.S. Food and Drug Administration granted accelerated approval to Replimune’s advanced melanoma treatment, to be marketed as Tudriqev, following an advisory committee’s supportive vote. Simultaneously, a consumer advocacy group … Read More
The National Institutes of Health plans to restrict eligibility for its Pathways to Independence Award, known as the K99/R00 grant, limiting the key funding avenue strictly to U.S. citizens, permanent … Read More
The California Supreme Court has ruled in favor of Gilead Sciences in a closely watched lawsuit involving more than 24,000 patients. The plaintiffs argued the pharmaceutical company acted negligently by … Read More
Senate leadership released a bipartisan government funding stopgap measure on Sunday that would temporarily block a White House proposal granting political appointees direct control over federal research grants. The continuing … Read More
A divided Michigan Supreme Court ruled in a 4-to-3 decision that the state’s attorney general may proceed with an investigation into Eli Lilly over its insulin pricing practices. The ruling … Read More
A U.S. Food and Drug Administration advisory panel voted 10-to-3 to recommend Replimune’s experimental engineered viral immunotherapy, RP1, for advanced melanoma. Simultaneously, the weight loss drug market is experiencing a … Read More
The Trump administration has revised a planned pilot for the 340B Drug Pricing Program, permitting select pharmaceutical companies to issue timely rebates to certain hospitals and clinics instead of upfront … Read More
The American Diabetes Association faces mounting pressure after expelling five diabetes experts from its scientific meeting in New Orleans. Over 200 members now demand the resignations of CEO Charles Henderson … Read More
An FDA advisory panel recommended allowing compounding pharmacies to manufacture the peptide epitalon while narrowly voting against emideltide. The decisions follow a series of votes driven by health secretary Robert … Read More
Active medication shortages have climbed to 227, while GSK has officially halted development of its chronic cough candidate, camlipixant, following unsuccessful Phase 3 clinical trial results regarding efficacy benchmarks. In … Read More
